Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic disorders characterized by low blood counts and a tendency to progress to acute myeloid leukemia. Treatment options have increased over the past 10 years, and many new agents are currently being investigated. In this article, we review the diagnosis of MDS, prognostic systems, and treatment options, including supportive care, erythropoiesis-stimulating agents, antithymocyte globulin, lenalidomide, azacitidine, decitabine, intensive chemotherapy, and hematopoietic cell transplantation.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
-
Comment
MeSH terms
-
Antilymphocyte Serum / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Azacitidine / administration & dosage
-
Azacitidine / analogs & derivatives
-
Clinical Trials as Topic
-
Decitabine
-
Disease-Free Survival
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
-
Hematinics / adverse effects
-
Hematinics / therapeutic use*
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Immunologic Factors / therapeutic use
-
Iron Chelating Agents / therapeutic use*
-
Lenalidomide
-
Myelodysplastic Syndromes / diagnosis*
-
Myelodysplastic Syndromes / drug therapy
-
Myelodysplastic Syndromes / therapy*
-
Survival Analysis
-
Thalidomide / administration & dosage
-
Thalidomide / analogs & derivatives
-
Treatment Outcome
Substances
-
Antilymphocyte Serum
-
Hematinics
-
Immunologic Factors
-
Iron Chelating Agents
-
Granulocyte Colony-Stimulating Factor
-
Thalidomide
-
Decitabine
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
Lenalidomide
-
Azacitidine